Clinical colorectal cancer, ISSN 1533-0028 vol. 5, suppl. 2, November 2005
S. 57-105 : il., tab. ; 28 cm
- MeSH
- ErbB Receptors antagonists & inhibitors MeSH
- Colorectal Neoplasms therapy MeSH
- Publication type
- Collected Work MeSH
- Conspectus
- Patologie. Klinická medicína
- NML Fields
- gastroenterologie
- onkologie
Drugs, ISSN 0012-6667 vol. 60, suppl. 1, 2000
42 s. : tab., grafy ; 26 cm
Receptory pro epidermální růstové faktory (c-erbB/HER) zahrnují receptor pro epidermální růstový faktor (c-erbB-1/EGFR/HER-1) a tři další homologa; c-erbB-2-4/HER-2-4. Tento receptorový systém hraje zásadní roli v regulaci apoptózy, migrace, invazivity a metastázování, proliferace, adhezivity a diferenciace buněk. Změny exprese těchto receptorů jsou spojeny se špatnou prognózou četných nádorů. Z důvodu pochopení jejich významu v nádorové biologii a pro využití těchto receptorů jako míst cíleného terapeutického zásahu probíhá v současné době jejich intenzivní výzkum. V klinické praxi se začíná využívat řada specifických i nespecifických inhibitorů.
The epidermal growth factor receptor (c-erbB/HER) system comprises the epidermal growth factor receptor (c-erbB-1/EGFR/HER-1) and three other homologues c-erbB-2-4/HER-2-4. This receptor system plays a critical role in apoptosis, migration, cell invasivity and metastasis, proliferation, adhezivity and differentiation of the cells. Changes of statut this receptors has been associated with poor prognosis in cancer of numerous tumors. Recently, these receptors have been intensely studied to understand is their importance in cancer biology and as therapeutic targets, and many specific and non-specific c-erbB inhibitors are developed for use.
- MeSH
- ErbB Receptors analysis genetics chemistry MeSH
- Research Support as Topic MeSH
- Receptor Cross-Talk immunology drug effects MeSH
- Neoplasm Invasiveness genetics immunology physiopathology MeSH
- Humans MeSH
- Neoplasm Metastasis genetics immunology physiopathology MeSH
- Antibodies, Monoclonal administration & dosage immunology therapeutic use MeSH
- Check Tag
- Humans MeSH
Biologická léčba při ovlivňování přirozených regulačních mechanismů řídících metabolismus, proliferaci a migraci nádorových buněk využívá nízkomolekulární preparáty, makromolekuly i buněčné efektory imunitního typu. V současnosti je nejvíce mformaci o ovlivnění receptoru pro epidermální růstový faktor (epidermal growth factor receptor = EGFR). Velmi intenzivně je zkoumána možnost inhibice intracelulární domény EGF receptoru s tyrozinkinázovou aktivitou. Jedna se o terapeutický přístup na subcelulární úrovni. Tato onkologická léčba je cílená (tzv. „targeted") na nitrobuněčné mechanismy přenosu signálu, který vyvolává změny proliferační aktivity nádorových buněk. Ve svém sdělení se autorky zabývají různými možnostmi ovlivnění EGFR a uplatněním v klinické praxi.
To influence natural regulatory mechanisms, which control the metabolism, proliferation and migration of tumour cells, biological therapy resorts to low-molecular preparations, macromolecules and cellular immune-type effectors. Today we have primarily information on the influencing of the epidermal growth factor receptor - EGFR. Research concentrates abcbove all on the possibility of inhibiting the intracelular domains of the EGF receptor that has a tyrosinekinase activity. This oncological treatment targets intracellular mechanisms of the transfer of the signal that calls forth changes in the proliferation activity of tumour cells. In their paper the authors discuss various possibilities of influencing EGFR and their application in clinical practice.
- Keywords
- ZD 1839, OSI-774,
- MeSH
- Carcinoma, Bronchogenic drug therapy MeSH
- Cetuximab MeSH
- ErbB Receptors antagonists & inhibitors chemistry MeSH
- Humans MeSH
- Antibodies, Monoclonal pharmacology MeSH
- Antineoplastic Agents pharmacology therapeutic use MeSH
- Signal Transduction MeSH
- Trastuzumab MeSH
- Protein-Tyrosine Kinases antagonists & inhibitors MeSH
- Check Tag
- Humans MeSH
Seminars in oncology, ISSN 0093-7754 vol. 29, no. 5, suppl. 14, October 2002
69 s. : il., tab. ; 28 cm
- MeSH
- ErbB Receptors MeSH
- Angiogenesis Inhibitors therapeutic use MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Neoplasms drug therapy MeSH
- Publication type
- Collected Work MeSH
- Conspectus
- Patologie. Klinická medicína
- NML Fields
- onkologie
- farmacie a farmakologie
- farmakoterapie
Seminars in oncology, ISSN 0093-7754 vol. 30, no. 3, suppl. 7, June 2003
53 s. : il., tab. ; 28 cm
- MeSH
- Quinazolines pharmacokinetics pharmacology therapeutic use MeSH
- ErbB Receptors MeSH
- Clinical Protocols MeSH
- Molecular Biology methods MeSH
- Neoplasms drug therapy MeSH
- Publication type
- Collected Work MeSH
- Conspectus
- Patologie. Klinická medicína
- NML Fields
- onkologie
- farmakoterapie
Epidermal growth factor receptor (EGFR) plays an important role in cell-cycle regulation, proliferation, differentiation, and surviving of epithelial tissues. Aberrant overexpression of EGFR can initiate uncontrolled cell proliferation with subsequent formation of epithelial carcinomas. Correlation between EGFR overexpression and increased resistance of tumor tissues to ionizing radiation has been described by many authors. Strategy of tumor radiosensitization by EGFR inhibition seems to have a great potential in the treatment of epithelial cancers. Rationale for EGFR inhibition in combination with ionizing radiaton arises from published results of many radiobiological studies, which describe the role of EGFR in cytoprotective and pro-proliferative reactions of human tumor cells, induced by irradiation. These reactions result in accelerated tumor repopulation, which is subsequently counter-productive to the effect of radiotherapy. Presented article is an overview of EGFR and its function in healthy and tumor tissues; likewise, it describes the relation of EGFR to ionizing radiation; therapeutic approaches to EGFR function modulation in combination with radiotherapy in preclinical and clinical use.
Seminars in oncology, ISSN 0093-7754 vol. 30, no. 1, suppl. 1, February 2003
55 s. : il., tab. ; 28 cm
- MeSH
- Chemotherapy, Adjuvant methods MeSH
- ErbB Receptors MeSH
- Evidence-Based Medicine MeSH
- Neoplasms therapy MeSH
- Carcinoma, Non-Small-Cell Lung therapy MeSH
- Receptor Protein-Tyrosine Kinases MeSH
- Publication type
- Collected Work MeSH
- Conspectus
- Patologie. Klinická medicína
- NML Fields
- onkologie
- biochemie
- farmacie a farmakologie
V poslednom desaťročí sa v klinickej praxi začali uplatňovať nové protinádorové preparáty označované pre svoj špecifický účinok termínom „cielená“ liečba. Prostriedkami cielenej terapie sú monoklonálne protilátky, inhibítory tyrozínkináz, inhibítory proteazómov a angiogenézy. Napriek ich nespornému medicínskemu prínosu sa s využitím tejto terapie spája množstvo nežiadúcich účinkov, pričom medzi najčastejšie radíme nežiaduce účinky na kožu. Tieto prejavy sú veľmi často pozorované pri terapii látkami inhibujúcimi aktivitu epidermálneho rastového faktora a jeho receptora.
In the last decade a new agents of anticancer therapy have been introduced. These agents include monoclonal antibodies, tyrosine kinase inhibitors, proteasome inhibitors and inhibitors of angiogenesis. Even though the targeted therapy is very effective it is associated with a lot of different side-effects, of which cutaneous are the most common. These are very often observed during therapy with inhibitors of epidermal growth factor and of its receptor.
- MeSH
- Acneiform Eruptions chemically induced classification MeSH
- Alopecia chemically induced MeSH
- ErbB Receptors antagonists & inhibitors MeSH
- Skin Diseases chemically induced MeSH
- Humans MeSH
- Antibodies, Monoclonal adverse effects MeSH
- Paronychia chemically induced MeSH
- Antineoplastic Agents adverse effects therapeutic use MeSH
- Pruritus chemically induced MeSH
- Check Tag
- Humans MeSH
